Retrospective analysis of oncogenic human papilloma virus and Epstein-Barr virus prevalence in Turkish nasopharyngeal cancer patients

Doğan, Hayriye Tatlı; Kılıçarslan, Aydan; Dogan, Mehmet; Süngü, Nuran; Tezel, Gaye Güler; Güler, Gülnur

doi:10.1016/j.prp.2016.08.013

Cited by 10 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By using PCR to amplify the EBER region, Janse and his colleagues 24 examined the incidence of EBV in 38 NPC patients, their study indicates that EBV was found in 82 % (31/38) of the tumours. Increased prevalence of infection by EBV was also reported in Nasopharyngeal cancer patients in previous studies, in Saudi Arabia (96%) 17, China 24 , and Turkey (87%) 25 . On the contrary, a previous report from Ghana Asante et al 26 showed a low 25% detection rate of EBV in NPC.…”

Section: Discussionsupporting

confidence: 70%

Detection of Epstein-Barr virus infections in Egyptian Nasopharyngeal Carcinoma patients

Youness,

EL-Ageery,

degla

et al. 2024

Egyptian Journal of Medical Microbiology

View full text Add to dashboard Cite

Background: Epstein Barr Virus (EBV) is associated with at least 1% of global cancers including nasopharyngeal cancer (NPC). The EBV DNA importance in the prediction of NPC has received little attention in non-endemic areas. Objective of the current study was to investigate the frequency of EBV in NPC patients compared to control of healthy individuals, and to study the relationship between EBV infection and clinicopathological and demographic characteristics. Methodology:A Case control study was conducted at the Hospital of Mansoura University. Fresh biopsies were collected from NPC patients and healthy controls over 2-years period between 2021 and 2023. After previous DNA extraction, real-time polymerase chain reaction was performed for EBV detection. Results:The study included a total of 28 patient biopsies proven NPC and 32 control individuals. A significantly higher prevalence of EBV in patients as compared with controls. The presence of the EBV infection was determined in half of the NPC patients and 6.3% of the control group. There was none statistically significant association between the presence of EBV and the clinicopathological features. Conclusion: EBV is prevalent in the NPC cases compared with controls. Further studies with a larger sample size are required to determine the true burden of EBV-associated NPC in Egypt

show abstract

Section: Discussionsupporting

confidence: 70%

Detection of Epstein-Barr virus infections in Egyptian Nasopharyngeal Carcinoma patients

Youness,

EL-Ageery,

degla

et al. 2024

Egyptian Journal of Medical Microbiology

View full text Add to dashboard Cite

show abstract

“…Although the focus for NPC is on EBV, a sub-group of these patients may feature HPV positive disease 15,23–25,27,42–47 . In agreement with recently reported data from a Finnish NPC cohort 24 , 15% of the tumours examined in this study were HPV positive, which is, as expected, less than for OPC but more than for other head and neck cancers.…”

Section: Discussionmentioning

confidence: 99%

Intralesional EBV-DNA load as marker of prognosis for nasopharyngeal cancer

Nilsson

Forslund

Andersson

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Nasopharyngeal cancer (NPC) is associated with the Epstein-Barr virus (EBV). The clinical presentation and prognosis of NPC is well described, but not in relation to intralesional EBV-DNA load. In a retrospective design, 48 patients with NPC were examined. Patient history was re-evaluated, and diagnostic biopsies were re-examined. Furthermore, intralesional EBV-DNA was quantitated and HPV status determined. Cancer stage, disease-free survival (DFS), and overall survival (OS) were assessed. Of the 48 patients, 36 (75%) patients featured lesions that were positive for EBER (Epstein–Barr virus-encoded small RNA) and 40 (83%) were positive for EBV-DNA. Seven patients (15%) were HPV positive. The levels of EBV-DNA ranged from 0.0005 to 94617 copies/cell. An EBV-DNA load of more than 70 copies/cell was associated with a prolonged DFS for EBV-DNA positive patients treated with curative intent (p = 0.046). In conclusion, the EBV-DNA load in NPC lesions appears to vary greatly. For patients with EBV-DNA positive NPC treated with curative intent, an EBV-DNA load of more than 70 copies/cell is associated with a better outcome in terms of 7-year DFS.

show abstract

“…Therefore, it is difficult to ascertain clinical factors associated with HPV‐positive versus HPV‐negative disease. Moreover, as a result of small‐volume reports, there are conflicting data as to whether or not HPV is associated with an improved prognosis in NPC . Indeed, as the focus of HPV‐induced OPC enters the realm of phase III trials that could change clinical management, it is becoming increasingly critical to address with large‐volume investigations whether there are links between HPV and prognoses in other head and neck neoplasms.…”

Section: Introductionmentioning

confidence: 99%